APD811: Phase I data

A double-blind, placebo-controlled Phase I trial in 32 healthy volunteers showed that single doses of 0.03, 0.05, 0.1 and 0.2 mg oral APD811 were rapidly absorbed and showed dose-proportional PK expos...